Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|March 8, 2021
Long Term Cognitive Decline in People Living With HIV
Author(s)Killian Meara
Change was associated with risk factors that have not been reported like chronic lung disease.
Advertisement
The brain is one of the main targets of the
There have been many studies that have assessed cognitive decline in people with HIV (PWH) over the span of a few years. However, there have never been any that have looked at cognitive change over the course of a decade or more.
Recently, investigators have assessed the cognitive decline in PWH over a 12 year period. The data was presented during the
The study included 397 participants who were part of the 6-site, U.S. CHARTER project and were assessed for cognitive change at an initial visit and at a follow up visit 12 years later. The change was assessed via a neuropsychological test battery that assessed 7 cognitive domains as well as medical history, prescribed medications, drug use, and blood collection.
The outcome was calculated using a regression-based change score (RBCS) with normative data from people without HIV. Decline was defined as change worse than the 5th percentile of the normative data.
The mean age at the 12-year visit was 56, with 23% being women, 58% having race or ethnicity other than white, and 96% having taken antiretroviral therapy (ART) for a mean of 15.3 years.
Findings from the study showed that 23.4% of the participants met the criterion for cognitive decline. The best model showed worse RBCS was associated with chronic lung disease. The model also showed people with diabetes and major depressive disorder (MDD) had worse cognitive decline than people with diabetes without MDD or people with neither condition.
Additionally, hypertension combined with diabetes and chronic lung disease was incrementally associated with a cognitive decline. Overall, a quarter of PWH experienced cognitive decline over the 12 years study period and those with aging-related risk factors had a worse change than those without.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Advertisement
Advertisement